DIRS.INFO The most relevant business & tech news

☆ Final Trades: Cisco Systems, Arch Capital, Pfizer, and the COWZ
▼ + stars: | 2024-07-17 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Cisco Systems, Arch Capital, Pfizer, and the COWZThe Investment Committee give you their top stocks to watch for the second half.

Organizations: Cisco Systems, Arch Capital, Pfizer, Investment

☆ Trade Tracker: Josh Brown gets stopped out of Sharkninja and Pfizer hits its highest level of 2024
▼ + stars: | 2024-07-17 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: Josh Brown gets stopped out of Sharkninja and Pfizer hits its highest level of 2024Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to discuss his latest trade out of Sharkninja, and how he's thinking about Pfizer at these levels.

Persons: Josh Brown Organizations: Pfizer, Ritholtz Wealth Management

☆ Work from home could lead to more homes in vacant offices
▼ + stars: | 2024-07-17 | by ( Samantha Delouya | ) edition.cnn.com time to read: +7 min

At first glance, The Crosby, an apartment building that opened in 2020 in Los Angeles’ Koreatown neighborhood, seems like a typical luxury high-rise. And most office buildings have central air conditioning, so the system needs to be replaced with individual cooling and heating systems for each unit. “Only about 15% of office buildings here in the markets that we’re based in are potentially good candidates for office-to-housing conversions,” Sherman said. While that may initially seem like a positive, apartment units need to have access to windows facing the exterior. Local governments aren’t only pushing for office building conversions, though.

Persons: CBRE, Crosby, West, ”, Jaime Lee, “, we’ve, ” Lee, Chris Sherman, ” Sherman, Sherman, you’re, Jason Ward, Ward, Eric Adams, John Watson, ” Watson, Watson, Kelly Wilkinson Organizations: CNN, Moody’s, Texaco, Jamison Group, ”, Jamison, Sherman Associates, “, Local, RAND, Housing, Homelessness, New York City, Pfizer, Indianapolis Star Locations: United States, Los Angeles, Koreatown, West Coast, Minneapolis, New York, New, Indianapolis, “, Indiana University's

☆ Pfizer advances development of once-daily formulation of oral weight loss pill
▼ + stars: | 2024-07-11 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer advances development of once-daily formulation of oral weight loss pillCNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Pfizer.

Persons: Angelica Peebles Organizations: Pfizer

☆ Thursday was a historically strange day in the stock market. That may be good news
▼ + stars: | 2024-07-11 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +2 min

Wall Street saw a dramatic shift in market trends on Thursday, with winning and losing stocks swapping places for a day. The Russell 2000 small-cap index, which has struggled to find its footing all year, jumped more than 3% on Thursday. Thursday was just the second day since 1979 when the Russell 2000 rose more than 3% while the S&P 500 declined. The Nasdaq Composite underperformed the Russell 2000 by more than 5 percentage points in what appears to be biggest daily gap on record. "Today's an important day," Ed Yardeni of Yardeni Research said on CNBC's "Closing Bell.

Persons: Russell, Ed Yardeni, Jerome Powell Organizations: Nvidia, Apple, Nasdaq, Investment Group, Pfizer, Yardeni Research, Federal Reserve

☆ Pfizer moves forward with once-daily version of weight loss pill after setbacks
▼ + stars: | 2024-07-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw "encouraging" data in an ongoing early-stage trial. Pfizer is one of several drugmakers racing to win a slice of the market for a highly popular class of weight loss and diabetes drugs called GLP-1 agonists. At the time, the pharmaceutical giant said phase one trial data on the once-daily version would "inform a path forward." Pfizer's danuglipron is a GLP-1 that promotes weight loss in the same way as Novo Nordisk' s injection Wegovy and diabetes treatment Ozempic. But he said Pfizer was looking for potential licensing deals or earlier-stage weight loss drugs.

Persons: Albert Bourla, Pfizer's, Eli Lilly, Bourla, Mikael Dolsten, Dolsten Organizations: Pfizer, Novo Nordisk, U.S

☆ Stocks making the biggest moves premarket: Delta Air Lines, Costco Wholesale, Pfizer and more
▼ + stars: | 2024-07-11 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

Delta Air Lines — Shares tumbled 9% after the airline issued a lower-than-expected sales growth forecast in the current quarter. Net income also fell 30% in the second quarter despite revenue reaching record highs. Costco Wholesale — Costco shares added nearly 3% after the wholesale club raised its membership fee for the first time since 2017 . Alcoa — The aluminum producer's shares rose 2.7% after releasing preliminary second-quarter results that came in stronger than expectations. MicroStrategy – MicroStrategy shares rose more than 4% after the bitcoin development company announced a 10-for-1 stock split .

Persons: Morgan Stanley, Jefferies, MicroStrategy, —, Jesse Pound, Tanaya Macheel, Michelle Fox, Alex Harring, Hakyung Kim, Sarah Min Organizations: Delta Air Lines, Costco Wholesale, Costco, Pfizer, PepsiCo —, Pepsi, Semiconductor, Darden, Jefferies, Alcoa, FactSet, FactSet . Revenue, Spotify Locations: U.S, Canada, FactSet .

☆ Final Trades: Pfizer, L3Harris Tech, the RSP and GDX
▼ + stars: | 2024-07-11 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Pfizer, L3Harris Tech, the RSP and GDXThe Investment Committee give you their top stocks to watch for the second half.

Organizations: Pfizer, L3Harris Tech, RSP, Investment

☆ Three-Stock Lunch: Apple, Pfizer and Delta Air Lines
▼ + stars: | 2024-07-11 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThree-Stock Lunch: Apple, Pfizer and Delta Air LinesMichael Farr, Hightower Advisors chief investment strategist, joins 'Power Lunch' to discuss stock plays for three stocks.

Persons: Michael Farr, Hightower Organizations: Apple, Pfizer, Delta Air, Hightower Advisors

☆ Pfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared Holz
▼ + stars: | 2024-07-11 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared HolzJared Holz, Mizuho, joins 'Fast Money' to talk what impact, if any, the Pfizer weight-loss drug trial will have on the stock.

Persons: Jared Holz Jared Holz Organizations: Pfizer Locations: Mizuho

☆ Ad giant Omnicom lifts the lid on its new generative AI platform ArtBotAI, which it says improves ad performance by 40%
▼ + stars: | 2024-07-10 | by ( Lara O'Reilly | ) www.businessinsider.com time to read: +6 min

The execs leading ArtBotAI said it differs from other ad agency holding groups' AI offerings because it builds on the ArtBot content automation tool its Critical Mass agency originally launched in 2022. "It's not just a generative AI tool, it's an automation tool that has been operationalized with large accounts at scale." Related storiesArtBotAI's generative AI functionality is driven by Omnicom's large language models, which it has created through partnerships with companies including Microsoft, OpenAI, Google, Getty, Adobe, and Amazon. KAITLIN MOERMANOmnicom said clients using ArtBotAI have, on average, achieved 40% increases in ad engagements like clicks and video views since they began using the platform. Omnicom stated in its February financial filings that its use of generative AI presents risks like ethical considerations, a negative impact on the public perception of the company, and the need to comply with various regulations.

Persons: —, ArtBotAI, ArtBot, Paolo Yuvienco, It's, Artbot, Yuvienco, Valerie Vargas, Alissa Hansen, KAITLIN MOERMAN Omnicom, Omnicom, Hansen, Ingo Duckerschein, Duckerschein Organizations: Service, Business, Apple, Unilever, Pfizer, Volkswagen, Omni, Omni Assist, Microsoft, Google, Getty, Adobe, Advertising, United Talent Agency, Agency, WPP, Intuit, Taboola Locations: North America

☆ Rural retailer Tractor Supply eliminates DEI roles, Pride support and carbon emissions goals
▼ + stars: | 2024-06-28 | by ( Ece Yildirim | In Ecedyildirim | ) www.cnbc.com time to read: +3 min

Shoppers are seen at the parking lot of a Tractor Supply Co. store near Bloomsburg. Tractor Supply is also retiring initiatives aimed at reducing environmental impact and improving employee diversity. Tractor Supply said it's making the changes to better represent the values of the communities and customers it serves. "Rural communities are the backbone of our nation and what make America great," Tractor Supply said in the news release. CNBC contacted Tractor Supply for more details about the changes, and the company declined to comment beyond the release.

Organizations: Tractor Supply Co, Bloomsburg . Tractor, Human Rights, Pride, Human, Pride Month, Tractor Supply, ", FFA, CNBC, Supreme, Starbucks, Disney, Target, Pfizer, Associated Press Locations: Bloomsburg, America

☆ Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
▼ + stars: | 2024-06-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +19 min

But other current employees are dissatisfied with where the strategy shift has left them. In January 2023, Pfizer forecast a steep drop in annual revenue, to between $67 billion and $71 billion. Pfizer's 2023 revenue ultimately came in at $58.5 billion, including $11.22 billion from its Covid vaccine and $1.28 billion from Paxlovid. Faith in executive leadership also plunged among some workers, according to most of the current and former employees who spoke with CNBC. Some current workers said that hasn't appeared to change after the town hall on May 2.

Persons: Albert Bourla, Wall, they're, Bourla, I'm, drugmaker Seagen, Irfan Khan, hasn't, Pfizer, renegotiating, John Thys, Payal Sahni Becher, Becher, Kena, Mike McDermott, Bourla's Organizations: Corbis, Getty, Pfizer, Wall, CNBC, Los Angeles Times, Moderna, Centers for Disease Control, U.S ., GSK, Bristol Myers Squibb, Pfizer wasn't, . Biotech, Companies, Biotech, BioNtech, Reuters, Human, View Press, Global, APEC, Summit, Tech, Google Locations: U.S, Covid, Eagle Rock , California, Durham , North Carolina, Puurs, Belgium, New York City, Peapack , New Jersey, Kena

☆ Palantir and Pfizer CEOs meet U.S. Senators to press for Israel support and hostage release
▼ + stars: | 2024-06-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPalantir and Pfizer CEOs meet U.S. Senators to press for Israel support and hostage releaseAlex Karp, Palantir CEO and Albert Bourla, Pfizer CEO, sit down with CNBC's Sara Eisen to discuss the Israel-Hamas War and antisemitism.

Persons: Alex Karp, Palantir, Albert Bourla, CNBC's Sara Eisen Organizations: Pfizer, U.S, Senators Locations: Israel

☆ Pfizer & Palantir CEOs speak out on Israel-Hamas war and antisemitism
▼ + stars: | 2024-06-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer & Palantir CEOs speak out on Israel-Hamas war and antisemitismAlex Karp, Palantir CEO and Albert Bourla, Pfizer CEO, sit down with CNBC's Sara Eisen to discuss the Israel-Hamas War and antisemitism.

Persons: Alex Karp, Palantir, Albert Bourla, CNBC's Sara Eisen Organizations: Pfizer, Palantir Locations: Israel

☆ Cramer: Pfizer's Covid sales tapered off much quicker than anyone expected
▼ + stars: | 2024-06-14 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Cramer: Pfizer's Covid sales tapered off much quicker than anyone expectedCNBC's Jim Cramer breaks down his take on Pfizer shares.

Persons: Cramer, Pfizer's, Jim Cramer Organizations: Pfizer

☆ CNBC Daily Open: Apple upgrades Siri with AI
▼ + stars: | 2024-06-11 | by ( Abid Ali | ) www.cnbc.com time to read: +3 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Apple IntelligenceShares of Apple fell 1.9% after the iPhone maker delivered its long-awaited AI strategy. Siri will get an upgrade with Apple Intelligence and access to OpenAI's ChatGPT. Investors are concerned Apple had fallen behind its rivals, Microsoft and Google, in the race to deliver AI services and tools.

Persons: Goldman Sachs, Siri, Apple, Elon Musk's, Chris Ailman, CNBC's, Ailman, CalSTRS, Elliott, Moderna, Tesla, Elon, Bernstein Organizations: CNBC, Nasdaq, Technology, Nvidia, Meta, Microsoft, Dow Jones, Apple Intelligence, Apple, Investors, Google, California State Teachers, Elliott, Southwest, Elliott Management, Southwest Airlines, Boeing, Pfizer, Novavax Locations: U.S

☆ Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
▼ + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. Moderna's messenger RNA combination shot, called mRNA-1083, is made up of both the company's vaccine candidate for seasonal influenza and a newer, "next-generation" version of its Covid shot. The study compared the combination shot with an enhanced flu vaccine called Fluzone HD and Moderna's currently licensed Covid shot, Spikevax, in one group of patients ages 65 and above. Moderna is also developing a combination shot targeting the flu and RSV, and another vaccine targeting all three respiratory viruses: Covid, flu and RSV. Meanwhile, Pfizer and BioNTech also are studying a vaccine that targets both Covid and the flu in a late-stage trial.

Persons: Stephane Bancel, Novavax, Bancel, Moderna, BioNTech Organizations: Pfizer, Novavax, Moderna, Covid Locations: U.S

☆ FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
▼ + stars: | 2024-06-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

But the virus can also cause severe illness in adults 50 and up — or even younger — with underlying chronic conditions such as asthma, diabetes and congestive heart failure. GSK's shot won't reach that new patient population just yet. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK. Regulatory agencies in Europe, Japan and other areas are currently reviewing GSK's application to expand Arexvy's approval to high-risk adults ages 50 to 59. GSK's shot is approved in nearly 50 countries, a spokesperson for the company told CNBC.

Persons: Phil Dormitzer, Dormitzer, Luke Miels, Arexvy, GSK's Organizations: Drug Administration, GSK, FDA, Centers for Disease Control, CNBC, CDC, Pfizer, Moderna, U.S Locations: British, Europe, Japan

☆ Nobel Prize-winning chemist Thomas R. Cech on ‘The Catalyst’ and the future of RNA
▼ + stars: | 2024-06-05 | by ( Saira Mueller | ) edition.cnn.com time to read: +13 min

“We saw that with the mRNA (messenger RNA) vaccines that it can be a good messenger,” says Cech. The Catalyst by Thomas R. Cech W W NortonYou mentioned in “The Catalyst” that research on RNA has been around since the ‘50s. What is something that most people get wrong about mRNA vaccines, such as the Covid-19 ones? Thomas R. Cech in a lab in 1984, five years before he won the Nobel Prize in Chemistry. How does this apply to DNA, RNA, mRNA and CRISPR?

Persons: you’re, ”, Thomas R, Cech, ” Cech, Sidney Altman, he’s, Norton, It’s, Thomas R . Cech, — Organizations: CNN, Pfizer, DNA, University of Colorado, Denver Post, Rotary Clubs, Lions Locations: Moderna, University of Colorado , Boulder, Boulder , Colorado, China, Cambridge , Massachusetts, United States, Germany

☆ Final Trades: Pfizer, Alphabet, Ventas and ASML Holding
▼ + stars: | 2024-06-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Pfizer, Alphabet, Ventas and ASML HoldingThe Investment Committee share their top stocks to watch for the second half.

Organizations: Pfizer, ASML, Investment

☆ Pfizer CEO: Cancer drugs will be our next big contribution to the world
▼ + stars: | 2024-06-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer CEO: Cancer drugs will be our next big contribution to the worldPfizer CEO Albert Bourla joins 'Squawk on the Street' to discuss the company's recent lung cancer drug data, how the drug could change the company's revenues, and more.

Persons: Albert Bourla Organizations: Pfizer, Cancer

☆ Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
▼ + stars: | 2024-06-03 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. LONDON — Shares of British pharmaceuticals giant GSK plunged 9% Monday, after a U.S. court ruled that scientific evidence could be presented in a stack of lawsuits relating to the discontinued heartburn drug Zantac. The Delaware State Court late on Friday ruled that plaintiffs' expert witnesses could testify in the roughly 75,000 cases alleging the once-popular drug ranitidine — sold under the brand name Zantac in the U.S. — may cause cancer. The companies involved deny there is a scientific consensus that the drug can be linked to any later development of cancers. In a statement Friday, GSK said it disagreed with the latest Delaware ruling and would immediately seek an appeal.

Persons: ranitidine —, Brent Wisner, Wisner Baum, Zantac Organizations: GlaxoSmithKline, Stevenage, GSK, Delaware State Court, France's, Pfizer, Germany's Locations: Britain, Delaware, U.S, France's Sanofi

☆ CNBC Daily Open: Opec extends cuts, Nvidia showcases new chip
▼ + stars: | 2024-06-03 | by ( Abid Ali | ) www.cnbc.com time to read: +3 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. OPEC+ extends cutsOPEC and it allies agreed to extend official crude production cuts into 2025 amid lackluster demand. Saudi Arabia's energy minister Prince Abdulaziz bin Salman said OPEC+ wants concrete rate cuts before factoring in the potential impact on energy demand. New AI chip RubinNvidia unveiled its next generation artificial intelligence chip, Rubin, a mere three months after launching its Blackwell model.

Persons: Prince Abdulaziz bin Salman, Rubin, Blackwell, Dow, UnitedHealth, Bill Ackman, It's, Michael Khouw Organizations: CNBC, Saudi Aramco, Rubin Nvidia, AMD, Intel, Microsoft, Google, Dow Jones, Federal, Dow, Nasdaq, Nvidia, Tesla, Pershing, Moderna, Drug Administration, GSK, Pfizer Locations: OPEC, Saudi Arabia, Russia, Saudi, U.S, Moderna

☆ These stocks are the most hated on the Street, but their fundamentals are improving
▼ + stars: | 2024-05-31 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Some stocks on Wall Street are absolutely hated by analysts and investors, but their fundamentals are improving, leaving a potential buying opportunity for contrarian investors, according to UBS. Most analysts currently covering the stock have assigned it a hold rating, with predicted upside of about 16% to consensus price targets. "The iconic automaker continues to enjoy strong profits from its core markets and a policy driven investment cycle in the U.S," the analyst wrote. Most analysts have assigned Airbnb stock a hold rating. The analyst consensus has shares at a hold rating, with predictions suggesting the stock could rise an average of 26% from its Thursday close.

Persons: Jonathan Golub, Bernstein, Daniel Roeska's, Wedbush, Scott Devitt, Ben Chaiken, Jan, Chaiken, Clorox, Estee Lauder, — CNBC's Michael Bloom Organizations: UBS, Stocks, Wall, Ford Motor, Ford, Cruise, Mizuho, Pfizer, Gartner, Northern Trust

Search resuls for: "Pfizer"

25 mentions found